Metsera, Inc. MTSR
Set alert
70.50 USD 0.00 0.00%
At close · Nov 13
70.13 Day range 70.76
51.92 52-week range 83.86
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 70.74
- Prev close
- 70.50
- Mkt cap
- 7.43B
- Vol
- 27.87M
- Avg vol
- 4.84M
- EPS
- -6.32
- P/E
- -39.83
- Div yield
- 0.00%
More statistics
- Low
- 70.13
- High
- 70.76
- Beta
- 1.70
- Inst. own
- 90.24%
- Dividend
- 0.00
- Earnings
- Mar 25, 2026
2Y chart
Events in this range
- Mar 26, 2025Earnings: -3.52; estimate -0.8; surprise -340%
- May 12, 2025Earnings: -1.03; estimate -0.85; surprise -21.18%
- Jun 10, 2025Rating: Guggenheim · Buy → Buy
- Jun 20, 2025Rating: Wells Fargo · — → Overweight
- Jul 28, 2025Earnings: -0.66; estimate -0.65811; surprise -0.29%
- Aug 28, 2025Rating: B of A Securities · Buy → Buy
- Sep 3, 2025Rating: Cantor Fitzgerald · Overweight → Overweight
- Sep 9, 2025Rating: Leerink Partners · — → Outperform
- Sep 24, 2025Downgrade: Leerink Partners · Outperform → Market Perform
- Nov 12, 2025Earnings: -1.11; estimate -0.56; surprise -98.21%
Signals (26)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2025 | 1 year ago |
| RSI: Overbought | Oct 30, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| RSI: Overbought | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 16, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Aug 27, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 22, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 25, 2025 | 1 year ago |
| RSI: Overbought | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 10, 2025 | 1 year ago |
| RSI: Overbought | Jun 10, 2025 | 1 year ago |
| MACD: Sell Signal | May 30, 2025 | 1 year ago |
| SMA: Bullish | May 8, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
Key statistics
- Market cap
- 7.43B
- Enterprise value
- 6.98B
- Trailing P/E
- -39.83
- PEG ratio
- -16.63
- Price / sales
- 0.00
- Price / book
- 21.96
- Beta
- 1.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -47.04%
Analyst view
Price target (mean) —
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 25, 2026
Expected Mar 25, 2026. Consensus EPS estimate -0.54.
Financials — quick view
MTSR Revenue — quarterly 0
MTSR Net income — quarterly -116.23M
MTSR EPS — quarterly -1.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2026 | Dec 31, 2025 | -0.54 | — | — | — |
| Nov 12, 2025 | Sep 30, 2025 | -0.56 | -1.11 | -0.55 | -98.21% |
| Jul 28, 2025 | Jun 30, 2025 | -0.65811 | -0.66 | 0.00 | -0.29% |
| May 12, 2025 | Mar 31, 2025 | -0.85 | -1.03 | -0.18 | -21.18% |
| Mar 26, 2025 | Dec 31, 2024 | -0.80 | -3.52 | -2.72 | -340.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Sep 9, 2025 | Leerink Partners | init | — | Outperform |
| Sep 3, 2025 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 28, 2025 | B of A Securities | main | Buy | Buy |
| Jun 20, 2025 | Wells Fargo | init | — | Overweight |
| Jun 10, 2025 | Guggenheim | main | Buy | Buy |
About Metsera, Inc.
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 93
- Website
- pfizer.com
News
- Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside
- IP Group shares jump 9% as Metsera deal drives return to growth
- Metsera Inc. (NASDAQ:MTSR) Given Average Recommendation of “Hold” by Brokerages
- Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market
- Ozempic Maker Novo Nordisk Faces Board Shakeup
- Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
- Pfizer Completes Acquisition of Metsera
- Metsera shareholders vote for $10 billion acquisition by Pfizer
- Why Metsera's Share Price Is Plummeting This Week
- Instacart Up on Earnings Beat; Metsera Down on Takeover Battle | Stock Movers
Your note
Sign in to keep a note on MTSR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS XII, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 2, 2025 | 0 |
| BERNS PAUL L | Director | Purchase | Feb 2, 2025 | 0 |
| BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 2, 2025 | 0 |
| FMR LLC | Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Nov 9, 2025 | 0 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jan 29, 2025 | 1,857,700 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.18% | 13,891,986 | 979.39M | Sep 29, 2025 |
| Vanguard Group Inc | 5.53% | 5,824,993 | 410.66M | Sep 29, 2025 |
| Janus Henderson Group PLC | 5.08% | 5,352,751 | 377.37M | Sep 29, 2025 |
| Blackrock Inc. | 3.64% | 3,835,309 | 270.39M | Sep 29, 2025 |
| Alphabet Inc. | 3.59% | 3,783,528 | 266.74M | Sep 29, 2025 |
| VR Adviser, LLC | 3.56% | 3,750,662 | 264.42M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.44% | 3,629,742 | 255.90M | Sep 29, 2025 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.00% | 2,106,441 | 148.50M | Jul 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.90% | 1,998,569 | 140.90M | Sep 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.42% | 1,495,117 | 105.41M | Sep 29, 2025 |
| SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF | 1.27% | 1,336,340 | 94.21M | Sep 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.26% | 1,323,999 | 93.34M | Sep 29, 2025 |